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 ABSTRACT 
Wide-spread fasciculations are a characteristic feature in amyotrophic lateral sclerosis (ALS), 
suggesting motor axonal hyperexcitability. Previous excitability studies have shown increased 
nodal persistent sodium conductances and decreased potassium currents in motor axons of ALS 
patients, both of the changes inducing hyperexcitability. Altered axonal excitability potentially 
contributes to motor neuron death in ALS, but the relationship of the extent of motor neuronal 
death and abnormal excitability has not been fully elucidated. We performed multiple nerve 
excitability measurements in the median nerve at the wrist of 140 ALS patients and analyzed the 
relationship of compound muscle action potential (CMAP) amplitude (index of motor neuronal 
loss) and excitability indices, such as strength-duration time constant, threshold electreotonus, 
recovery cycle and current-threshold relationships. Compared to age-matched normal controls 
(n=44), ALS patients (n=140) had longer strength-duration time constant (SDTC: a measure of 
nodal persistent sodium current; p < 0.05), greater threshold changes in depolarizing threshold 
electrotonus (p < 0.05) and depolarizing current threshold relationship (i.e. less accommodation; 
(p < 0.05), greater superexcitability (a measure of fast potassium current; p < 0.05) and reduced 
late subexcitability (a measure of slow potassium current; p < 0.05), suggesting increased 
persistent sodium currents and decreased potassium currents. The reduced potassium currents 
were found even in the patient subgroups with normal CMAP (> 5mV). Regression analyses 
showed that low R-values of CMAP amplitude decline with SDTC (R = -0.22) and depolarizing 
threshold electrotonus (R = -0.22). These findings suggest that motor nerve hyperexcitability 
occurs in the early stage of the disease, and precedes motor neuronal loss in ALS. Modulation of 
altered ion channel function could be a treatment option for ALS.   
  
 Introduction 
From the date of Charcot, pathomechanisms of upper and lower motor neuron degeneration in 
amyotrophic lateral sclerosis (ALS) have not been fully elucidated [1]. Probably, multiple 
pathomechanisms underlie the development of motor neuron death, with motor neuronal 
hyperexcitability potentially contributing to it [2]. Wide-spread fasciculations are a specific 
feature of ALS and suggest motor nerve terminal hyperexcitability [3, 4]. Actually, in ALS 
motor axons, increased sodium and decreased potassium currents, both of these inducing 
hyperexcitability, have been reported [5-8]. Glutamate is the main excitatory neurotransmitter in 
the central nervous system, and excessive glutamate induces neurodegeneration, known as 
excitotoxicity [9, 10]. Futhermore, ALS motor neuron has decreased capacity for Ca
2+
 influx 
[11]. As such, motor neuronal hyperexcitability appears to contribute to motor neuronal 
degeneration. Riluzole is known to lower the concentration of glutamate in the synaptic cleft and 
support this hypothesis [12]. 
 
While the association of motor neuronal hyperexcitability with motor neuron death has been 
gradually revealed, the relationship of the extent of motor axonal loss and axonal 
hyperexcitability has not been fully elucidated. Prior study followed up nerve excitability 
findings in 37 ALS patients during 3 months, relatively short period, and concluded that 
potassium currents decrease along with disease progression [13], although the onset of nerve 
hyperexcitability and long term alterations remain unknown. Briefly, it is not proven whether 
excitability alteration precedes onset of axonal loss and how excitability changes during long 
periods of time. If excitability alteration precedes the onset of axonal loss, it may suggest that 
hyperexcitability is relatively upstream of motor neuronal degeneration process. 
  
To disclose the association of the extent of motor neuronal death with axonal hyerexcitability, 
we cross-sectionally performed nerve excitability testing in over 100 ALS patients and analyzed 
these. Our findings may reveal the connection between nerve excitability and motor neuron 
death and suggest therapeutic options. 
 Materials and methods 
Subjects 
Consecutive patients with ALS were seen at Chiba University Hospital from January 2001 
through to September 2014 and were included into this study. The following patients were 
excluded: patients with a family history of motor neuron disease, genetically proven hereditary 
ALS, patients with concomitant disease which affects peripheral nerve, such as diabetes mellitus 
and carpal tunnel syndrome, patients with severe axonal loss in the median nerve, in which we 
could not perform excitability testing or patients who took riluzole at the time of testing. Patients 
fulfilled the revised El Escorial criteria for definite or probable ALS [14]. Control data for nerve 
excitability measurements were obtained from 44 age- and gender-matched normal controls (22 
men; age, 51 to 86 years, mean 64.2 years). None of them had clinical or electrophysiological 
evidence of a peripheral nerve or lower motor neuron disorder. All subjects gave informed 
consent, and the study was approved by the Ethics Committee of Chiba University School of 
Medicine. 
 
Nerve conduction study 
Standard nerve conduction study was performed in all patients to exclude differential diagnosis. 
CMAP amplitude in abductor pollicis brevis (APB) muscle was picked up for analyses. 
 
Multiple Excitability Measurements 
Multiple excitability properties were measured for the median nerve at the wrist and recorded 
from abductor APB muscle, (QTRAC with multiple protocol TRONDXM2 or NF, Institute of 
 Neurology, London, UK), as reported elsewhere (Shibuya et al., 2015, 2013, 2011). Skin 
temperature near the stimulus site was maintained > 32ºC. The following excitability indices 
were included; strength-duration time constant (SDTC), threshold electrotonus (TE), 
refractoriness, superexcitability, and late subexcitability of the recovery cycle of axonal 
excitability with a single supramaximal conditioning stimulus and current threshold relationship.   
 
Statistical Analysis 
All statistical tests were two-sided. To compare total ALS cohort and normal controls, unpaired 
t-test or Fisher’s exact test were performed. In subanalysis, ALS patients were divided into two 
groups according to CMAP amplitudes in APB muscle. CMAP cut-off value was set as 5mV 
because this is normal cut-off value of our laboratory, measured in 101 normal controls. In this 
analysis, Dunnett test was executed.   
To examine the relationship between CMAP amplitude and nerve excitability indices, Pearson’s 
correlation coefficient was used.  
Data are presented as mean ± SE. The level of statistical significance was established at P < 0.05. 
In regression analyses, r > 0.2 and P < 0.05 were judged as significant relationship. All statistical 
analyses were performed SPSS Statistics version 22 software. 
  
 Results 
Clinical profiles 
One hundred forty patients who met the inclusion criteria were enrolled. Clinical profiles in ALS 
patients are shown in Table1. Their mean age was 66.6 ± 0.8, and 55% were male. These were 
not significantly different from the control group. Mean disease duration was 16.5 ± 1.2 months, 
and first symptom affected the limb regions in 69% patients. Mean CMAP was 4.5 ± 0.3 mV. 
Table 1. Clinical and neurophysiological profiles in 140 ALS patients   
 
  
Amyotrophic lateral sclerosis 
Normal (n = 44) 
All (n = 140) CMAP > 5mV (n = 53) CMAP < 5mV (n = 87) 
Clinical profiles 
  
Age at assessment (year)     66.6 (0.8) 64.6 (1.2) 67.8 (1.1) 64.2 (1.4) 
  
Gender (male: female)     77: 63 29: 24 48: 39 22: 22 
  
Disease duration (month)     16.5 (1.2) 13.8 (1.2) 18.1 (1.7)   
  
Site of onset (bulbar; arm; leg)     43; 49; 48 21; 9; 23 22; 40; 25   
Nerve conduction study  
  
CMAP amplitude (Median 
nerve) 
  (mV) 4.5 (0.3) 7.8 (0.3) 2.5 (0.1)   
Nerve excitability testing 
  
Strength-duration time 
constant  
  (ms) 0.48 (0.01)* 0.45 (0.01) 0.50 (0.02)* 0.43 (0.01) 
  Threshold electrotonus             
    TEd (10-30 ms)  (%) 71.3 (0.9)* 70.0 (0.7) 72.1 (1.4)* 66.1 (0.9) 
    TEd (90-100 ms)  (%) 52.2 (0.8)* 49.6 (0.8)* 53.8 (1.2)* 44.5 (0.9) 
    TEh (90-100 ms)  (%) -129.8 (2.3) -130.9 (3.0) -129.2 (3.2) -120.7 (4.0) 
  Recovery cycle 
    Refractoriness  (%) 20.4 (2.7) 18.5 (2.8) 21.6 (4.1) 13.3 (3.7) 
    Superexcitability  (%) -28.6 (0.7)* -28.2 (0.8)* -28.9 (1.0)* -21.0 (1.2) 
    Late subexcitability  (%) 13.0 (0.5)* 14.0 (0.8) 12.4 (0.7)* 16.3 (0.7) 
  Current threshold relationship             
    40% depolarizing current  (%) 51.9 (0.9)* 48.9 (0.7)* 53.6 (1.4)* 43.6 (1.0) 
    
100% hyperpolarizing 
current  
(%) -302.0 (6.6) -312.4 (8.2) -295.8 (9.3) -299.6 (8.6) 
ALS = amyotrophic lateral sclerosis; CMAP = compound muscle action potential; TE = threshold electrotonus; Data are given as mean (SE). *P < 0.05, compared 
with normal values 
 
Excitability alterations in ALS cohort 
 Results of multiple excitability measurements are shown in Table1 and Fig1. Compared to 
normal subjects, significantly longer SDTC, greater depolarizing threshold electrotonus (TEd), 
greater superexcitability and reduced late subexcitability in recovery cycle and greater reduction 
of threshold in 40% depolarizing current in current threshold relationship were demonstrated in 
the total ALS cohort (n = 140). These findings suggest increased persistent sodium conductances 
and decreased fast and slow potassium currents.  
 
Fig 1. Nerve excitability indices in healthy control and ALS. 
Averaged excitability indices in normal controls (NC) (n = 44) and total amyotrophic lateral 
sclerosis (ALS) cohort (n = 142). Compared to NC, significant greater strength-duration time 
constant (SDTC) (*p < 0.05) (A), greater depolarizing threshold electrotonus (TEd) (TEd 
10-30ms and TEd 90-100ms; *p < 0.05) (B), increased superexcitabilty (*p < 0.05) and reduced 
late subexcitability (*p < 0.05) in recovery cycle (C) and increased 40% depolarizing currents in 
current threshold relationship (I/V) (*p < 0.05) (D) were found in amyotrophic lateral sclerosis 
(ALS) patients. Data are given as mean ± SE. 
 
Also in the subgroup analysis, ALS patients with under 5mV CMAP amplitude had similar 
findings. Significantly longer SDTC, greater TEd, greater superexcitability and reduced late 
subexcitability in recovery cycle and greater reduction of threshold in 40% depolarizing current 
in current threshold relationship were found in this ALS cohort (n = 87) (Table1). ALS patients 
with over 5mV CMAP amplitude demonstrated similar findings, although extents of these 
differences were less evident, and SDTC and late subexcitability alterations did not reach 
significant differences. These results suggest that decreased potassium currents are obvious even 
in patients with preserved CMAP amplitudes, and increased sodium and decreased potassium 
 currents were more prominent in patients with severe axonal loss. 
 
Association of excitability indices with CMAP amplitude 
Results of correlation analyses between CMAP amplitude and excitability indices are shown in 
Table2 and Fig2. SDTC (p = 0.01, R = -0.22) and TEd 90-100ms (p = 0.01, R = -0.022) were 
significantly related to CMAP amplitude and were increased with CMAP decline. These findings 
suggest that increased persistent sodium and decreased slow potassium currents are significantly 
related to axonal loss and become prominent with axonal loss. TEd 10-30ms (R = -0.087) was 
increased, and superexcitability (R = 0.067), late subexcitability (R = 0.013) and threshold in 
40% depolarizing currents (R = -0.019) were decreased with CMAP decline. Although these 
were not significantly associated with CMAP amplitude, these alteration were consistent with the 
previous result, decreased potassium currents with CMAP decline. 
 
Fig 2. Scatter plots of nerve excitability indices and CMAP amplitudes. 
Scatter plots of nerve excitability indices and compound muscle action potential (CMAP) 
amplitudes in 140 ALS patients. These indices were recorded over the abductor pollicis brevis 
(APB) muscle, stimulated in the median nerve at the wrist. SDTC (A) (p = 0.01, r = -0.22), 
superexcitability (B) (p = 0.45, r = 0.067) and TEd 90-100ms (C) (p = 0.01, r = -0.22) were 
increased with CMAP decline. Approximate lines are shown in each index. These findings 
suggest increased persistent sodium and decreased potassium currents deteriorate with axonal 
loss. Open circles represent normal average ± 1.96SE value in each index.   
  
 Table 2. The correlation between nerve excitability indice and CMAP amplitude 
Nerve excitability indice Results of correlation analyses 
Strength-duration time constant     (ms) p = 0.01 R = -0.22 
Threshold electrotonus 
  TEd (10-30 ms)  (%) p = 0.19 R = -0.11 
  TEd (90-100 ms)  (%) p = 0.01 R = -0.22 
  TEh (90-100 ms)   (%) p = 0.67 R = -0.04 
Recovery cycle 
  Refractoriness   (%) p = 0.96 R = 0.004 
  Superexcitability   (%) p = 0.45 R= 0.067 
  Late subexcitability   (%) p = 0.07 R = 0.16  
Current threshold relationship 
  40% depolarizing current   (%) p = 0.03 R = -0.19 
  100% hyperpolarizing current   (%) p = 0.10 R = -0.15 
TE = threshold electrotonus 
   
 Discussion 
Our 140 ALS patient data demonstrated increased persistent sodium conductances and decreased 
potassium currents in peripheral motor axons, suggesting motor axonal hyperexcitability. 
Reduced potassium currents were evident even in patients with preserved CMAP. Increased 
persistent sodium conductance and decreased slow potassium currents were significantly related 
to CMAP amplitude and deteriorate with axonal loss. These findings suggest motor axonal 
hyperexcitability precedes axonal loss. 
 
Our analyses suggested motor nerve hyperexcitability appears in patients with preserved CMAP. 
As described earlier, motor axonal hyperexcitability potentially contributes to motor neuron 
death, although the onset of this alteration has not been elucidated. Our findings suggest that 
nerve hyperexcitability, especially decreased potassium currents, precedes axonal loss. 
Peripheral nerve hyperexcitability may increases Ca
2+ 
influx in lower motor neuron, lead to 
activation of degenerative enzymes, cause mitochondorial dysfunction, produce free radical, 
cause impaired production of adenosime triphosphate and result in motor neuron death [12]. As 
such, peripheral nerve hyperexcitability may be in the relatively upstream in the degenerative 
process of ALS neurodegeneration. Prior electromyogram study revealed fasciculation potential 
is a very early marker of ALS and heads denervation potential and muscle weakness [15]. Their 
study may support our findings. While significantly decreased potassium currents were found in 
patients with preserved CMAP, increased persistent sodium currents were not. Potassium 
currents are measured using 3 parameters, TE, recovery cycle and current threshold relationship, 
although the parameter of persistent sodium currents is only one, SDTC. Additionally, it is 
already reported that persistent sodium currents are strongly related to prognosis [16], suggesting 
 that persistent sodium currents are potentially associated with motor neuron death in ALS. As 
such, further validations are necessary for this discrepancy. In any case, motor axonal 
hyperexcitability, at least decreased potassium currents, may precede axonal loss. If nerve 
hyperexcitability contributes to degenerative pathway in ALS, ion channel modulators could be 
potential therapeutic drugs for ALS treatment [17].  
 
Altered channel dysfunctions were more prominent in patients with axonal loss, compared to 
preserved axons. Additionally, these trends were also found in regression analyses of all nerve 
excitability measurements (SDTC, TE, recovery cycle and current threshold relationship). These 
results may suggest that axonal hyperexcitability becomes prominent with axonal loss. As noted 
previously, one longitudinal study revealed that potassium currents decrease with disease 
progression and are consistent with our findings [13]. Separately, our 58 ALS data previously 
demonstrated that increased sodium currents are found in patient with preserved CMAP, and 
decreased potassium currents are exhibited in patient with moderately decreased CMAP [5]. In 
the present study, our large cohort, including 58 previous data, might make it clearer. Several 
studies disclosed the relationship between ALS pathology and hyperexcitability [18-20]. One 
study demonstrated motor neuronal cell line, transfected with transactivation response element 
DNA binding protein 43 (TDP-43), has hyperexcitability [21]. Additionally, if ALS pathology, 
such as TDP-43, propagates through transcellular pathyway, “prion-like propagation”, ALS 
pathological changes may gradually lead motor neuronal hyperexcitability from cell to cell 
[22-24]. Separately, our prior autopsy study revealed markedly reduced potassium channel 
expression in ALS motor axon [6]. These results and hypotheses may support our findings. 
However, further validation is necessary for our asumptions, because significant relationships 
between CMAP amplitude and excitability indices were found only in SDTC and TEd 90-100ms. 
  
A limitation of this study is that CMAP amplitude was used as a marker of axonal loss. In the 
condition of axonal loss, renervations affect CMAP amplitude. Neurophysiological index, which 
is calculated from CMAP amplitude, distal motor latency and F-wave frequency, or motor 
unit number estimation may be more suitable for evaluating ALS axonal loss [25,26]. However, 
CMAP amplitude also reflects and significantly related to axonal loss, and our large cohort may 
diminish this limitation [26]. Moreover, to validate our findings, longitudinal neurophysiological 
follow-up from the time of early disease stage may be helpful.   
 
This study suggests that nerve hyperexcitability is early features. Nerve hyperexcitability may 
induce motor neuron death and accelerate motor neuron death. These findings encourage us to 
think that ion channel modulators could be a therapeutic option for ALS treatment.  
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